Evaluating the Efficacy and Short-Term Prognosis of Integrated Traditional Chinese and Western Medicine for Ankylosing Spondylitis(AS): A Protocol for a Cohort Study
Evaluating the Efficacy and Short-Term Prognosis of Integrated Traditional Chinese and Western Medicine for Ankylosing Spondylitis(AS): A Protocol for a Prospective Multicenter Cohort Study
China-Japan Friendship Hospital
790 participants
Jan 19, 2026
OBSERVATIONAL
Conditions
Summary
This study is a multicenter, prospective cohort study designed to systematically evaluate the clinical efficacy of integrated Traditional Chinese and Western Medicine on short-term functional improvement in patients with ankylosing spondylitis, with the Bath Ankylosing Spondylitis Functional Index (BASFI) at 6 months of treatment as the primary outcome measure.
Eligibility
Inclusion Criteria3
- fulfill the 1984 modified New York criteria for ankylosing spondylitis or the 2009 Assessment of SpondyloArthritis International Society (ASAS) classification criteria for axial spondyloarthritis
- age between 18 and 75 years
- sign informed consent.
Exclusion Criteria5
- diagnosis of other autoimmune diseases besides the disease under investigation (e.g., rheumatoid arthritis, Sjögren's syndrome, erythema nodosum, myositis, etc.)
- pregnancy or lactation
- comorbid severe cardiovascular or cerebrovascular diseases, hepatic or renal failure, or malignancy
- spondyloarthritis related to enteropathic arthritis, psoriatic arthritis, or reactive arthritis
- unable to provide data due to mental, language, or similar factors.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07556224